keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial

keyword
https://www.readbyqxmd.com/read/29145401/anatomically-specific-intratubular-and-interstitial-biominerals-in-the-human-renal-medullo-papillary-complex
#1
Ling Chen, Ryan S Hsi, Feifei Yang, Benjamin A Sherer, Marshall L Stoller, Sunita P Ho
Limited information exists on the anatomically-specific early stage events leading to clinically detectable mineral aggregates in the renal papilla. In this study, quantitative multiscale correlative maps of structural, elemental and biochemical properties of whole medullo-papillary complexes from human kidneys were developed. Correlative maps of properties specific to the uriniferous and vascular tubules using high-resolution X-ray computed tomography, scanning and transmission electron microscopy, energy dispersive X-ray spectroscopy, and immunolocalization of noncollagenous proteins (NCPs) along with their association with anatomy specific biominerals were obtained...
2017: PloS One
https://www.readbyqxmd.com/read/29144939/re-efficacy-of-systemic-chemotherapy-plus-radical-nephroureterectomy-for-metastatic-upper-tract-urothelial-carcinoma
#2
M Pilar Laguna
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29143738/bladder-cancer-associated-mutations-in-rxra-activate-peroxisome-proliferator-activated-receptors-to-drive-urothelial-proliferation
#3
Angela M Halstead, Chiraag D Kapadia, Jennifer Bolzenius, Clarence E Chu, Andrew Schriefer, Lukas D Wartman, Gregory R Bowman, Vivek K Arora
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs). Analysis from the TCGA raised the possibility that hyperactive PPAR signaling, either due to PPAR gamma gene amplification or RXRA hot-spot mutation (S427F/Y) drives 20-25% of human bladder cancers. Here we characterize mutant RXRA, demonstrating it induces enhancer/promoter activity in the context of RXRA/PPAR heterodimers in human bladder cancer cells. Structure-function studies indicate that the RXRA substitution allosterically regulates the PPAR AF2 domain via an aromatic interaction with the terminal tyrosine found in PPARs...
November 16, 2017: ELife
https://www.readbyqxmd.com/read/29139108/a-3-untranslated-region-polymorphism-rs2304277-in-the-dna-repair-pathway-gene-ogg1-is-a-novel-risk-modulator-for-urothelial-bladder-carcinoma
#4
Tayyaba Ahmed, Saira Nawaz, Rabia Noreen, Kashif Sardar Bangash, Abdur Rauf, Muhammad Younis, Khursheed Anwar, Muhammad Athar Khawaja, Maleeha Azam, Abid Ali Qureshi, Saeed Akhter, Lambertus A Kiemeney, Raheel Qamar, Syeda Hafiza Benish Ali
Altered DNA repair capacity may affect an individual's susceptibility to cancers due to compromised genomic integrity. This study was designed to elucidate the association of selected polymorphisms in DNA repair genes with urothelial bladder carcinoma (UBC). OGG1 rs1052133 and rs2304277, XRCC1 rs1799782 and rs25487, XRCC3 rs861539, XPC rs2228001, and XPD rs13181 were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 UBC cases and 200 controls. We found association of OGG1 rs2304277 [odds ratio (OR)GG = 3...
November 15, 2017: Annals of Human Genetics
https://www.readbyqxmd.com/read/29139021/perioperative-complications-and-mortality-in-patients-with-urothelial-carcinoma-and-end-stage-renal-disease-undergoing-one-stage-complete-urinary-tract-extirpation
#5
Yun-Ching Huang, Ying-Hsu Chang, Alan W Shindel, Yin-Lun Chang, Jian-Hui Lin, Dong-Ru Ho, Chih-Shou Chen
BACKGROUND: Complete urinary tract extirpation (CUTE) is a complex procedure with substantial risk for perioperative complications. The association between clinical characteristics and the risk of major postoperative complications has not been systematically investigated. OBJECTIVE: The aim of this study was to analyze the incidence and risks for major perioperative complications after CUTE. METHODS: Respective chart review of 81 patients with urothelial carcinoma (UC) who were treated with one-stage CUTE between January 2004 and December 2015...
November 14, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29137333/preoperative-chronic-kidney-disease-predicts-poor-oncological-outcomes-after-radical-nephroureterectomy-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#6
Hirotake Kodama, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Go Anan, Ken Fukushi, Takuma Narita, Toshikazu Tanaka, Yuka Kubota, Hirotaka Horiguchi, Masaki Momota, Koichi Kido, Teppei Matsumoto, Osamu Soma, Itsuto Hamano, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Atsushi Sasaki, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Objective: To evaluate the impact of preoperative chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy. Methods: A total of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017 were retrospectively examined. Oncological outcomes, including intravesical recurrence-free, visceral recurrence-free, cancer-specific, and overall survival rates (intravesical RFS, visceral RFS, CSS, and OS, respectively) stratified by preoperative CKD status (CKD vs...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136187/a-phase-iii-trial-of-a-single-early-intravesical-instillation-of-pirarubicin-to-prevent-bladder-recurrence-after-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma-jcog1403-utuc-thp-phase-iii
#7
Kenichi Miyamoto, Akihiro Ito, Masashi Wakabayashi, Junko Eba, Yoichi Arai, Hiroyuki Nishiyama, Mikio Sugimoto, Ryo Yamashita, Yoshiyuki Kakehi
Observation is the current standard for managing cases of Stage 0a-III upper tract urothelial carcinoma after radical nephroureterectomy. A randomized Phase III trial commenced in Japan during October 2016. The trial is designed to investigate the superiority of a single early intravesical instillation of pirarubicin, compared with observation, in terms of relapse-free survival after radical nephroureterectomy for Stage 0a-III upper tract urothelial carcinoma. During a 5-year period, 310 patients will be recruited from 43 Japanese institutions...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29135410/tissue-based-molecular-markers-in-upper-tract-urothelial-carcinoma-and-their-prognostic-implications
#8
Ricardo L Favaretto, Stênio C Zequi, Renato A R Oliveira, Thiago Santana, Walter H Costa, Isabela W Cunha, Gustavo C Guimarães
Upper tract urothelial carcinoma (UTUC) is a rare and aggressive disease that is associated with high rates of recurrence and death. Radical nephroureterectomy (RNU) with excision of the bladder cuff is considered the standard of care for high-risk UTUC, whereas kidney-sparing techniques can be indicated for select patients with low-risk disease. There is a significant lack of clinical and pathological prognostic factors for stratifying patients with regard to making treatment decisions. Incorporation of tissue-based molecular markers into prognostic tools could help accurately stratify patients for clinical decision-making in this heterogeneous disease...
November 17, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29135284/atezolizumab-in-urothelial-bladder-carcinoma
#9
Zineb Hamilou, Pernelle Lavaud, Yohann Loriot
Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy. Recently, immune-checkpoint inhibitors transformed the management and prognosis of many malignancies and will certainly redefine the standard of care for bladder cancer. Atezolizumab, an antiprogrammed cell death ligand-1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016 for patients with urothelial carcinoma...
November 14, 2017: Future Oncology
https://www.readbyqxmd.com/read/29133939/precision-medicine-for-urothelial-bladder-cancer-update-on-tumour-genomics-and-immunotherapy
#10
REVIEW
Kenneth M Felsenstein, Dan Theodorescu
Effective management of advanced urothelial bladder cancer is challenging. New discoveries that improve our understanding of molecular bladder cancer subtypes have revealed numerous potentially targetable genomic alterations and demonstrated the efficacy of treatments that harness the immune system. These findings have begun to change paradigms of bladder cancer therapy. For example, DNA repair pathway mutations in genes such as ERCC2, FANCC, ATM, RB1, and others can predict responses to neoadjuvant platinum-based chemotherapies and to targeted therapies on the basis of mutation status...
November 14, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29133936/the-rho-gtpase-signalling-pathway-in-urothelial-carcinoma
#11
REVIEW
Solomon L Woldu, Ryan C Hutchinson, Laura-Maria Krabbe, Oner Sanli, Vitaly Margulis
Urothelial carcinoma remains a clinical challenge: non-muscle-invasive disease has a high rate of recurrence and risk of progression, and outcomes for patients with advanced disease are poor, owing to a lack of effective systemic therapies. The Rho GTPase family of enzymes was first identified >30 years ago and contains >20 members, which are divided into eight subfamilies: Cdc42, Rac, Rho, RhoUV, RhoBTB, RhoDF, RhoH, and Rnd. Rho GTPases are molecular on-off switches, which are increasingly being understood to have a critical role in a number of cellular processes, including cell migration, cell polarity, cell adhesion, cell cycle progression, and regulation of the cytoskeleton...
November 14, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29131763/immune-checkpoint-inhibitor-cancer-therapy-spectrum-of-imaging-findings
#12
Gary X Wang, Vikram Kurra, Justin F Gainor, Ryan J Sullivan, Keith T Flaherty, Susanna I Lee, Florian J Fintelmann
Immune checkpoint inhibitors are a new class of cancer therapeutics that have demonstrated striking successes in a rapid series of clinical trials. Consequently, these drugs have dramatically increased in clinical use since being first approved for advanced melanoma in 2011. Current indications in addition to melanoma are non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, and classical Hodgkin lymphoma. A small subset of patients treated with immune checkpoint inhibitors undergoes an atypical treatment response pattern termed pseudoprogression: New or enlarging lesions appear after initiation of therapy, thereby mimicking tumor progression, followed by an eventual decrease in total tumor burden...
November 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29130995/lncrna-uca1-promotes-mitochondrial-function-of-bladder-cancer-via-the-mir-195-arl2-signaling-pathway
#13
Hui-Jin Li, Xiao-Min Sun, Zheng-Kun Li, Qian-Wen Yin, Huan Pang, Jing-Jing Pan, Xu Li, Wei Chen
BACKGROUND/AIMS: This study aims to identify whether Urothelial Cancer Associated 1 (UCA1) regulates mitochondrial metabolic reprogramming in bladder cancer, and to explore how UCA1 participates in mitochondrial metabolism by the UCA1/miR-195/ARL2 signaling pathway; these findings may be aid in the development of tumor diagnostic and therapeutic strategies. METHODS: Bladder tissues were obtained from patients. Stable cell lines were constructed, with ectopic expression of UCA1 in UMUC2 cells and knockdown of UCA1 in 5637 cells...
November 1, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29130942/high-grade-urothelial-carcinoma-on-urine-cytology-resembling-umbrella-cells
#14
Andrew A Renshaw, Edwin W Gould
CONTEXT: High-grade urothelial carcinoma (UC) cells have many appearances on urine cytology, but according to The Paris System, they can be easily distinguished from umbrella cells. OBJECTIVE: We aimed to define the incidence and appearance of high-grade UC cells that resemble umbrella cells in Cytospin preparations on urine cytology. RESULTS: Cytospin preparations from 331 cases with biopsy follow-up (230 benign/low-grade and 101 malignant [22 carcinoma in situ, 52 papillary, 19 invasive UC, 8 other] cases) were reviewed...
November 11, 2017: Acta Cytologica
https://www.readbyqxmd.com/read/29126388/yrna-expression-predicts-survival-in-bladder-cancer-patients
#15
Yuri Tolkach, Anna Franziska Stahl, Eva-Maria Niehoff, Chenming Zhao, Glen Kristiansen, Stefan Cajetan Müller, Jörg Ellinger
BACKGROUND: Non-coding RNAs play an important role in human carcinogenesis. YRNAs (Ro-associated Y), a novel class of non-coding RNAs, have been identified as biomarker in various malignancies, but remain to be studied in urinary bladder cancer (BCA) patients. METHODS: The expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival BCA (urothelial carcinoma, n = 88) and normal urothelial bladder (n = 30) tissues using quantitative real-time PCR...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29125238/lncrna-uca1-promotes-proliferation-and-cisplatin-resistance-of-oral-squamous-cell-carcinoma-by-sunppressing-mir-184-expression
#16
Zheng Fang, Junfang Zhao, Weihong Xie, Qiang Sun, Haibin Wang, Bin Qiao
Chemotherapy resistance has become the main obstacle for the effective treatment of human cancers. Long non-coding RNA urothelial cancer associated 1 (UCA1) is generally regarded as an oncogene in some cancers. However, the function and molecular mechanism of UCA1 implicated in cisplatin (CDDP) chemoresistance of oral squamous cell carcinoma (OSCC) is still not fully established. UCA1 expression in tumor tissues and cells was tested by qRT-PCR. MTT, flow cytometry and caspase-3 activity analysis were explored to evaluate the CDDP sensitivity in OSCC cells...
November 10, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29123257/prostaglandin-receptors-induce-urothelial-tumourigenesis-as-well-as-bladder-cancer-progression-and-cisplatin-resistance-presumably-via-modulating-pten-expression
#17
Eiji Kashiwagi, Satoshi Inoue, Taichi Mizushima, Jinbo Chen, Hiroki Ide, Takashi Kawahara, Leonardo O Reis, Alexander S Baras, George J Netto, Hiroshi Miyamoto
BACKGROUND: We investigated the role of prostaglandin receptors (e.g. prostaglandin E2 receptor 2 (EP2), EP4) and the efficacy of celecoxib in urothelial tumourigenesis and cancer progression. METHODS: We performed immunohistochemistry in bladder cancer (BC) tissue microarrays, in vitro transformation assay in a normal urothelial SVHUC line, and western blot/reverse transcription-polymerase chain reaction/cell growth assays in BC lines. RESULTS: EP2/EP4 expression was elevated in BCs compared with non-neoplastic urothelial tissues and in BCs from those who were resistant to cisplatin-based neoadjuvant chemotherapy...
November 9, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29120910/biomarkers-for-immunotherapy-in-urological-cancers
#18
Kilian M Gust, Irene Resch, David D'Andrea
PURPOSE OF REVIEW: Immunotherapies for urological malignancies have made tremendous progress by targeting immune checkpoints and have been implemented in clinical practice nowadays. Though siginifcant number of patients does not respond to immunotherapy. Biomarkers could help to predict response to treatment, but are still under investigation. We reviewed the literature to identify relevant biomarkers in patient treated with immunotherapy. RECENT FINDINGS: A comprehensive search of PubMed through has been performed to identify important relevant publications from 2016 to 2017 on biomarkers for immunotherapies in urological cancers including reported clinical trials...
November 7, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29119638/biphasic-papillary-renal-cell-carcinoma-is-a-rare-morphologic-variant-with-frequent-multifocality-a-study-of-28-cases
#19
Kiril Trpkov, Daniel Athanazio, Cristina Magi-Galluzzi, Helene Yilmaz, David Clouston, Abbas Agaimy, Sean R Williamson, Fadi Brimo, Jose I Lopez, Monika Ulamec, Nathalie Rioux-Leclercq, Maysoun Kassem, Nilesh Gupta, Arndt Hartmann, Xavier Leroy, Samir Al Bashir, Asli Yilmaz, Ondřej Hes
AIMS: To further characterize biphasic squamoid renal cell carcinoma (RCC), a recently proposed variant of papillary RCC. METHODS AND RESULTS: We identified 28 tumors from multiple institutions. They typically demonstrated two cell populations - larger cells with eosinophilic cytoplasm and higher-grade nuclei, surrounded by smaller, amphophilic cells with scanty cytoplasm. The dual morphology was variable (median 72.5% of tumor, range 5-100%); emperipolesis was found in all cases...
November 8, 2017: Histopathology
https://www.readbyqxmd.com/read/29119053/enzalutamide-as-an-androgen-receptor-inhibitor-prevents-urothelial-tumorigenesis
#20
Takashi Kawahara, Satoshi Inoue, Eiji Kashiwagi, Jinbo Chen, Hiroki Ide, Taichi Mizushima, Yi Li, Yichun Zheng, Hiroshi Miyamoto
Emerging preclinical evidence suggests the critical role of androgen-mediated androgen receptor (AR) signals in the development of bladder cancer. However, little is known about the efficacy of enzalutamide, an AR signaling inhibitor, in androgen-induced urothelial tumorigenesis. We therefore aimed to assess the effects of enzalutamide on neoplastic transformation of urothelial cells. An immortalized normal urothelial cell line SVHUC stably expressing wild-type AR (SVHUC-AR) was exposed to a chemical carcinogen 3-methylcholanthrene (MCA) to induce neoplastic transformation, and subsequently cultured for 6 weeks in the presence of anti-androgens, including enzalutamide, hydroxyflutamide, and bicalutamide...
2017: American Journal of Cancer Research
keyword
keyword
4084
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"